203 related articles for article (PubMed ID: 31932694)
1. Autologous CAR T-cell therapies supply chain: challenges and opportunities?
Papathanasiou MM; Stamatis C; Lakelin M; Farid S; Titchener-Hooker N; Shah N
Cancer Gene Ther; 2020 Nov; 27(10-11):799-809. PubMed ID: 31932694
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
3. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
4. Improving CAR T-cells: The next generation.
Marple AH; Bonifant CL; Shah NN
Semin Hematol; 2020 Jul; 57(3):115-121. PubMed ID: 33256900
[TBL] [Abstract][Full Text] [Related]
5. Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery.
Lam C; Meinert E; Halioua-Haubold CL; Carter A; Yang A; Brindley D; Cui Z
BMJ Open; 2019 Jul; 9(7):e026172. PubMed ID: 31278092
[TBL] [Abstract][Full Text] [Related]
6. A guide to manufacturing CAR T cell therapies.
Vormittag P; Gunn R; Ghorashian S; Veraitch FS
Curr Opin Biotechnol; 2018 Oct; 53():164-181. PubMed ID: 29462761
[TBL] [Abstract][Full Text] [Related]
7. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
8. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
9. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
10. The making and function of CAR cells.
Zabel M; Tauber PA; Pickl WF
Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
[TBL] [Abstract][Full Text] [Related]
11. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing chimeric antigen receptor T cells: issues and challenges.
Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
18. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]